Predniso(lo)ne

Phase 3

Amgen

Predniso(lo)ne is one of 2 therapeutic programs targeting Primary Immune Thrombocytopenia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Primary Immune ThrombocytopeniaNot yet recruiting

Primary Immune ThrombocytopeniaPhase 3

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Primary Immune Thrombocytopenia

#DrugCompanyPhaseTrials

Nplate

Amgen

Phase 3

1 2

Predniso(lo)ne

Amgen

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Not yet recruiting

Primary Immune Thrombocytopenia

NCT07700238

Clinical

Trials by Indication[1]

Primary Immune Thrombocytopenia1 trial

A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Adults With Previously Untreated Primary Immune Thrombocytopenia (ITP).

Not yet recruiting· Amgen logo

Amgen·Phase 3·NCT07700238·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Predniso(lo)ne. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Predniso(lo)ne. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Amgen

Predniso(lo)ne

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Primary Immune Thrombocytopenia1 trial

References

Drug Info

Quick Facts

Related News